THE ACTIVITY YOU CAN SEE
Relapses reduced—up to 58%
STUDY 1
FEWER RELAPSES
COMPARED TO
AUBAGIO
STUDY 2
FEWER RELAPSES
COMPARED TO
AUBAGIO
Disability progression—it's less likely
Studies 1 & 2 Combined
LESS LIKELY
VS AUBAGIO
LESS LIKELY
VS AUBAGIO
*This was based on whether or not disability progression was still present 3 and 6 months after disability symptoms started.
THE ACTIVITY YOU DON'T SEE
Less active (T1) lesions—way less
STUDY 1
FEWER Gd+ T1 LESIONS
0.01 for KESIMPTA
VS
0.46 for AUBAGIO
On average per MRI
STUDY 2
FEWER Gd+ T1 LESIONS
0.03 for KESIMPTA
VS
0.52 for AUBAGIO
On average per MRI
Less new or enlarging (T2) lesions—a lot less
STUDY 1
FEWER T2 LESIONS
0.72 for KESIMPTA
VS
4.00 for AUBAGIO
Number per year
STUDY 2
FEWER T2 LESIONS
0.64 for KESIMPTA
VS
4.16 for AUBAGIO
Number per year
Gd+=gadolinium-enhancing; MRI=magnetic resonance imaging.

Since starting KESIMPTA, I've had fewer relapses, which is really cool. I love seeing that it's really working for me.
– MAGGIE S.
Maggie S. has taken KESIMPTA and has been compensated for her time. Individual results may vary.
Maggie S. has taken KESIMPTA and has been compensated for her time. Individual results may vary.
Learn about savings
and support.
ALONGSIDE™ KESIMPTA
Get tailored resources, tips, and
more for your specific needs,
including information on KESIMPTA.